Advertisement

Molecular Biology Reports

, Volume 41, Issue 2, pp 997–1001 | Cite as

Lack of association between cyclooxygenase 2−765G/C gene polymorphism and breast cancer risk in Ahvaz, west-south Iran

  • Behnaz Ahmadi
  • Abdolrahim Nikzamir
  • Seid Mohamadali Ghafari
  • Ghorban Mohamadzadeh
  • Mahmod Latifi
  • Ahmad Bafandeh
  • Mohammad Fathi
  • Mir Saeed Yekaninejad
  • Mahfam Nikzamir
Article

Abstract

Cyclooxygenases are key enzymes in conversion of arachidonic acid into prostaglandin H2. Cyclooxygenase-2 (COX-2) increases prostaglandins in neoplastic tissue. COX-2 has important roles in cell proliferation cancers, angiogenesis, and alzheimer. COX-2 is up-regulated in several types of cancer, and it is hypothesized that COX-2 expression may be genetically influenced. Our main objective was to evaluated the association of polymorphism COX-2 with risk of breast cancer in khouzestan province, and the second objective of the study was to evaluate the association with biochemistry parameters. This study consisting of 150 patients with breast cancer and 120 normal DNA was extracted from the white blood cells. Polymorphism cox2 gene was detected by polymerase chain reaction according to the standard methods. The profile lipids and estrogen were measured in two groups by standard methods. Chi square analysis showed that there was no association between breast cancer risk and COX-2 −765G>C genotype and alleles. Also, no association were observed between −765G>C polymorphism and biochemistry parameters. A multiple logistic regression model with cox2 genotypes and LDL and HDL as covariates revealed that there is no significant association between cox2 genotypes and risk of breast cancer, but higher values of LDL and HDL significantly increase risk of breast cancer.

Keywords

Cyclooxygenase gene Breast cancer Polymorphism 

Notes

Acknowledgments

The authors thank all the subjects for participating. This study was supported by the Department of Biochemistry, Faculty of Medicine, Ahvaz Jondishapour University of Medical sciences, Ahvaz, Iran.

References

  1. 1.
    Needleman P, Turk J, Jakschik BA et al (1986) Arachidonic acid metabolism. Annu Rev Biochem 55:69–102CrossRefPubMedGoogle Scholar
  2. 2.
    Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxidesynthases(cyclooxygenases)-1 and -2. J Biol Chem 271:33157–33160CrossRefPubMedGoogle Scholar
  3. 3.
    Zha S, Yegnasubramanian ZS, Nelson WG et al (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 205:1–20CrossRefGoogle Scholar
  4. 4.
    Wang JM, Ko CY, Chen LC et al (2006) Functional role of NF-IL6beta and its sumoylation and acetylation role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase-2 gene. Nucleic Acids Res 34:217–231CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gallicchio L, McSorley MA, Newschaffer CJ et al (2006) Nonsteroidal anti inflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106:1443–1452CrossRefPubMedGoogle Scholar
  6. 6.
    Pereira C, Sousa H, Ferreira P et al (2006) −765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 12:5473–5478CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Shahedi K, Lindstrom S, Zheng SL, Wiklundand et al (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119:668–672CrossRefPubMedGoogle Scholar
  8. 8.
    Ali IU, Luke BT, Dean M et al (2005) Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer 93:953–959CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    How LR, Subbaramaiah K, Brown AM et al (2001) Cyclooxygenase-2 a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97–114CrossRefGoogle Scholar
  10. 10.
    Saxena A, Prasad KN, Ghoshal UC et al (2008) Polymorphism of −765G>C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India. World J Gastroenterol 14:1498–1503CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tan W, Wu J, Zhang X et al (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28:1197–1201CrossRefPubMedGoogle Scholar
  13. 13.
    Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431–436CrossRefPubMedGoogle Scholar
  14. 14.
    Dannenberg AJ, Altorki NK, Boyle JO et al (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544–551CrossRefPubMedGoogle Scholar
  15. 15.
    Dannenberg AJ, Howe LR (2003) The role of COX-2 in breast and cervical cancer. Prog Exp Tumor Res 37:90–106CrossRefPubMedGoogle Scholar
  16. 16.
    Langsenlehner U, Yazdani-Biuki B, Eder T et al (2006) The cyclooxygenase-2 (PTGS2) 8473T > C polymorphism is associated with breast cancer risk. Clin Cancer Res 12:1392–1394CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang X, Miao X, Tan W et al (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129:565–576PubMedGoogle Scholar
  18. 18.
    Campa D, Zienolddiny S, Zienolddiny S, Maggini V et al (2004) Association of a common polymorphism in the cyclooxygenase-2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235CrossRefPubMedGoogle Scholar
  19. 19.
    Li F, Ren GS, Li HY et al (2009) A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol (R Coll Radiol) 4:302–305CrossRefGoogle Scholar
  20. 20.
    Ulrich CM, Whitton J, Yu JH, Sibert J et al (2005) PTGS2 (COX-2) −765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14(3):616–619CrossRefPubMedGoogle Scholar
  21. 21.
    Diogo NP, Juliana SF, Laura MA et al (2010) Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer 10:613CrossRefGoogle Scholar
  22. 22.
    Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenasesin inflammation, cancer, and development. Oncogene 18:7908–7916CrossRefPubMedGoogle Scholar
  23. 23.
    Zhu W, Wei BB, Shan X et al (2010) −765G>C and 8473T > C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37(1):277–288CrossRefPubMedGoogle Scholar
  24. 24.
    Xing L-L, Wang Z-N, Jiang L et al (2008) Cyclooxygenase-2 polymorphism and colorectal cancer: −765G>c variant modifies risk associated with smoking and body mass index. World J Gastroenterol 14(11):1785–1789CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Soslow RA, Dannenberg AJ, Rush D et al (2000) Cyclooxigenase is expressed in human pulmonary, colonic and mammary tumours. Cancer 89:2637–2645CrossRefPubMedGoogle Scholar
  26. 26.
    Singh-Ranger G, Mokbel K (2002) The role cyclooxygenase-2 (cox2) in breast cancer, and implication of cox2 inhibition. Eur J Surg Oncol 28:729–737CrossRefPubMedGoogle Scholar
  27. 27.
    Montali A, Barillà F, Tanzilli G et al (2010) Functional rs20417 SNP (−765G>C) of cyclooxygenase-2 gene does not predict the risk of recurrence of ischemic events in coronary patients: results of a 7-year prospective study. Cardiol J 115(3):236–242CrossRefGoogle Scholar
  28. 28.
    Kohsaka S, Volcik KA, Folsom AR et al (2008) Increased risk of incident stroke associated with the cyclooxygenase-2 (COX-2) G-765C polymorphism in African–Americans: the atherosclerosis risk in communities study. Atheroscler J 196(2):926–930CrossRefGoogle Scholar
  29. 29.
    Lee CR, North KE, Bray MS, Couper DJ et al (2008) Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 83(1):52–60Google Scholar
  30. 30.
    McKeown N (1999) Antioxidants and breast cancer. Nutr Rev 57:321–324PubMedGoogle Scholar
  31. 31.
    Wesseling C, Antich D, Hogstedt C et al (1999) Geographical differences of cancer incidence in Costa Rica in relation to environmental and occupational pesticide exposure. Int J Epidemiol 28:365–374CrossRefPubMedGoogle Scholar
  32. 32.
    Ulrich CM, Whitton J, Yu JH et al (2005) PTGS2 (COX-2) −765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14:616–619CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Behnaz Ahmadi
    • 1
  • Abdolrahim Nikzamir
    • 1
    • 2
  • Seid Mohamadali Ghafari
    • 1
  • Ghorban Mohamadzadeh
    • 1
  • Mahmod Latifi
    • 3
  • Ahmad Bafandeh
    • 1
  • Mohammad Fathi
    • 4
  • Mir Saeed Yekaninejad
    • 5
  • Mahfam Nikzamir
    • 6
  1. 1.Department of Biochemistry, Faculty of MedicineAhvaz Jondishapour University of Medical SciencesAhvazIran
  2. 2.Endocrine Research CenterValiasr Hospital, Tehran University of Medical SciencesTehranIran
  3. 3.Health Department, Faculty of HealthAhvaz Jondishapour University of Medical SciencesAhvazIran
  4. 4.Anesthesiology Department, Faculty of MedicineMofid Children’s Hospital, Shahid Beheshti University of Medical SciencesTehranIran
  5. 5.Department of Epidemiology and BiostatisticsSchool of Public Health, Tehran University of Medical SciencesTehranIran
  6. 6.Farzanegan 2 High SchoolNational Organization of Developing Exceptional TalentsTehranIran

Personalised recommendations